Delivery Order SPE2DB24D8001-SPE2DB25FKZSR

Award Date 5/15/25
Potential Completion Date 5/16/25
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $1,665.96 to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML pharmaceutical products, with a performance period extending to March 26, 2025. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a significant Indefinite Delivery Contract (IDC) valued at $999,999,999.00 as part of...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract has a ceiling value of $3,707.66 and a period of performance through February 24, 2025. The contract is for the delivery of pharmaceutical products, including ZEPBOUND 15 MG/0.5 ML PEN 0.5ML, to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
The Defense Logistics Agency (DLA) awarded a $1,730.82 firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the procurement of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML pharmaceutical products. This delivery order is part of Dakota Drug, Inc.'s larger $999,999,999.00 indefinite-delivery contract (SPE2DB24D8001) with the DLA Troop Support Medical's ECAT Generation V Program, which enables the company to provide a wide range of pharmaceutical and...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $6,219.22, is for the delivery of pharmaceutical products, medical supplies, and healthcare equipment, specifically ZEPBOUND 15 MG/0.5 ML PEN 0.5ML. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an Ultimate Completion Date of March 20, 2025. Dakota Drug, Inc. holds a significant single-award...
This federal contract award, valued at $1,705.26, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a delivery order awarded under DLA's ECAT Generation V Program, a large Indefinite Delivery Contract (IDC) with a ceiling value of $999,999,999.00 that enables Dakota Drug, Inc. to provide a range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,223.92, is for the delivery of ZEPBOUND 15 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract is a firm fixed-price, non-set-aside award with a performance period through April 4, 2025. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a significant Indefinite Delivery Contract...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKYYT, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business based in Anoka, Minnesota. The $2,994.06 firm fixed-price delivery order is for the provision of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program,...
This federal contract award, with ID SPE2DB24D8001|SPE2DB25FKZNH, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,828.26 firm fixed-price delivery order is for the supply of 4567886888 ZEPBOUND 12.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The award is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows...
This federal contract award, identified as SPE2DB24D8003 and SPE2DB25FJTJF, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a total ceiling value of $1,491.37. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is November 25, 2024. Dakota Drug, Inc. is a key supplier of...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The contract, valued at $4,704.09, is for the delivery of pharmaceutical products, specifically the drug Zepbound 5 mg/0.5 ml pen. The contract has an ultimate completion date of April 16, 2025 and was awarded on April 15, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00, which...
  • SPE2DB24D8001
    Indefinite Delivery Contract
  • SPE2DB24D8001-SPE2DB25FKZSR
    Delivery Order

This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA). The $3,074.85 firm fixed-price delivery order is for the supply of ZEPBOUND 15 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract has an ultimate completion date of May 16, 2025.

Dakota Drug, Inc. also holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, that is part of the DLA Troop Support Medical's ECAT Generation V Program and runs through December 31, 2025. This larger contract vehicle allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. The contract originates from DLA Troop Support Medical's solicitation SPE2DH-21-R-0002, which seeks proposals for commercial medical equipment, accessories, consumables, and medical simulation equipment used by medical professionals.

Generated 8/17/25, 1:20 AM